E
Elicio Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2012 · IPO 2023
Transforming the lives of patients and their families by re-engineering the body’s immune response to cancer MoreLess
Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. The company leverages the natural power of the lymph nodes to enhance the immune system's response against tumors. Elicio's targeted delivery approach aims to generate robust immune responses by activating and amplifying cancer-fighting T cells, potentially enabling patients to combat aggressive cancers more effectively. The company operates in the immuno-oncology market, serving patients battling various forms of cancer. Elicio's business model revolves around the research, development, and clinical trials of its proprietary therapies, with revenue generated through partnerships, grants, and future commercialization of successful treatments. The company's mission is to revolutionize cancer treatment by providing patients with the best possible outcomes through cutting-edge immunotherapy solutions.
Keywords: immunotherapy, lymph nodes, cancer treatment, T cells, biotechnology, clinical-stage, oncology, immune response, tumor targeting, cancer immunotherapies.
Company overview
Elicio Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Cambridge, United States
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 80.2
- Investment activity
- 1 companies · latest Jan 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Elicio Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jul 2026 | $15M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jan 2025 | $10M | — | Undisclosed | ↗ |
| POST IPO CONVERTIBLEOther financing | Aug 2024 | $20M | — | GKCC | ↗ |
| POST IPO EQUITYOther financing | Jun 2024 | $0 | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Dec 2023 | $7M | — | GKCC | ↗ |
| GRANTOther financing | Sep 2023 | Gastro-Intestinal Research Foundation | ↗ | ||
| IPOOther financing | Jan 2023 | Undisclosed | — | ||
| POST IPO DEBTDebt | Jan 2023 | Angion Biomedica | ↗ | ||
| GRANTOther financing | Sep 2022 | Undisclosed | ↗ | ||
| SERIES COther financing | May 2022 | Undisclosed | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$35M | — |
| 2025 | $0 | — | −$35M | — |
| 2024 | $0 | — | −$47M | — |
| 2023 | $0 | — | −$34M | — |
| 2022 | $0 | — | −$23M | — |
| 2021 | $0 | — | −$25M | — |
| 2020 | $0 | — | −$16M | — |
Growth signals
Elicio Therapeutics website traffic
Latest recorded traffic for Elicio Therapeutics is 7.4K monthly website visits, down 38.3% over the last three months. Elicio Therapeutics's team grew 9.3% over the past year.
Comparisons
Elicio Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Elicio Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Elicio Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Elicio Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Elicio Therapeutics has talent and traffic
team presence
In the news
Latest news about Elicio Therapeutics
Recent press, funding announcements, and product moves mentioning Elicio Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Elicio Therapeutics
An AI-synthesized read of the highest-engagement posts about Elicio Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elicio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.